metoclopramide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
sulpiride derivatives	1782	364-62-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: metoclopramide metoclopramide hydrochloride metochlopramide methochlopramide metoclopramide hydrochloride hydrate metoclopramide monohydrochloride metoclopramide HCl AHR-3070-C metaclopramide	A dopamine D2 antagonist that is used as an antiemetic. Molecular weight: 299.80 Formula: C14H22ClN3O2 CLOGP: 2.23 LIPINSKI: 0 HAC: 5 HDO: 2 TPSA: 67.59 ALOGS: -2.99 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

metoclopramide
metoclopramide hydrochloride
metochlopramide
methochlopramide
metoclopramide hydrochloride hydrate
metoclopramide monohydrochloride
metoclopramide HCl
AHR-3070-C
metaclopramide

A dopamine D2 antagonist that is used as an antiemetic.

Molecular weight: 299.80
Formula: C14H22ClN3O2
CLOGP: 2.23
LIPINSKI: 0
HAC: 5
HDO: 2
TPSA: 67.59
ALOGS: -2.99
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
30	mg	O
30	mg	P
30	mg	R

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	33.36 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ
S (Water solubility)	0.20 mg/mL	Hosey CM, Chan R, Benet LZ
EoM (Fraction excreted unchanged in urine)	20 %	Hosey CM, Chan R, Benet LZ
BA (Bioavailability)	76 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	3.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.60 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	7.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 7, 1979	FDA	BAXTER HLTHCARE CORP

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	1188.22	35.23	364	1722	46279	2309720
Dystonia	400.89	35.23	84	2002	2110	2353889
Tardive dyskinesia	386.04	35.23	78	2008	1626	2354373
Nausea	347.68	35.23	196	1890	111993	2244006
Serotonin syndrome	272.49	35.23	67	2019	3473	2352526
Vomiting	267.09	35.23	142	1944	71460	2284539
Toxicity to various agents	244.72	35.23	105	1981	32649	2323350
Toxic epidermal necrolysis	234.28	35.23	58	2028	3086	2352913
Drug interaction	212.72	35.23	92	1994	29071	2326928
Dyskinesia	205.45	35.23	57	2029	4732	2351267
Restlessness	203.54	35.23	56	2030	4507	2351492
Extrapyramidal disorder	198.69	35.23	48	2038	2299	2353700
Electrocardiogram QT prolonged	186.18	35.23	59	2027	7755	2348244
Drug abuse	180.06	35.23	64	2022	11962	2344037
Seizure	177.60	35.23	77	2009	24389	2331610
Akathisia	171.69	35.23	40	2046	1634	2354365
Tachycardia	171.25	35.23	67	2019	16342	2339657
Exposure during pregnancy	168.87	35.23	75	2011	25144	2330855
Tremor	166.32	35.23	70	2016	20591	2335408
Dyspnoea	162.87	35.23	107	1979	78626	2277373
Parkinsonism	149.24	35.23	35	2051	1470	2354529
Cardiac arrest	148.82	35.23	59	2027	14871	2341128
Anxiety	148.79	35.23	72	2014	29287	2326712
Atelectasis	130.02	35.23	33	2053	1932	2354067
Hypotension	124.64	35.23	66	2020	32370	2323629
Torsade de pointes	120.85	35.23	32	2054	2214	2353785
Fatigue	114.34	35.23	89	1997	84784	2271215
Blister	112.52	35.23	39	2047	6732	2349267
Stevens-Johnson syndrome	104.77	35.23	33	2053	4226	2351773
Electrolyte imbalance	104.73	35.23	28	2058	2009	2353990
Multiple organ dysfunction syndrome	104.17	35.23	38	2048	7603	2348396
Hyponatraemia	103.19	35.23	44	2042	13281	2342718
Asthenia	101.98	35.23	66	2020	46860	2309139
Cardio-respiratory arrest	101.08	35.23	39	2047	9107	2346892
Condition aggravated	100.45	35.23	57	2029	31922	2324077
Movement disorder	100.06	35.23	29	2057	2799	2353200
Neuroleptic malignant syndrome	99.45	35.23	27	2059	2053	2353946
Gastrointestinal disorder	98.45	35.23	38	2048	8879	2347120
Muscle twitching	96.26	35.23	28	2058	2737	2353262
Completed suicide	95.66	35.23	48	2038	20986	2335013
Maternal exposure during pregnancy	95.37	35.23	43	2043	14820	2341179
Confusional state	94.69	35.23	50	2036	24294	2331705
Phaeochromocytoma crisis	94.40	35.23	14	2072	36	2355963
Respiratory disorder	94.23	35.23	30	2056	3974	2352025
Respiratory arrest	92.73	35.23	33	2053	6145	2349854
Computerised tomogram thorax abnormal	90.36	35.23	16	2070	155	2355844
Anaphylactic reaction	88.41	35.23	36	2050	9669	2346330
Diarrhoea	85.90	35.23	75	2011	83489	2272510
Generalised tonic-clonic seizure	85.58	35.23	30	2056	5342	2350657
Hyperhidrosis	84.51	35.23	40	2046	15382	2340617
Decreased appetite	84.00	35.23	49	2037	28842	2327157
Cholecystitis	83.82	35.23	24	2062	2216	2353783
Economic problem	82.97	35.23	17	2069	375	2355624
Hypoxia	81.25	35.23	30	2056	6197	2349802
Hyperthyroidism	80.86	35.23	23	2063	2074	2353925
Agitation	80.61	35.23	35	2051	11016	2344983
Somnolence	79.47	35.23	44	2042	23441	2332558
Dermatitis exfoliative	77.92	35.23	20	2066	1221	2354778
Depression	77.27	35.23	46	2040	28086	2327913
Headache	74.47	35.23	68	2018	80111	2275888
Erythema	73.97	35.23	43	2043	25116	2330883
Hypertension	73.21	35.23	44	2042	27317	2328682
Oculogyric crisis	72.69	35.23	15	2071	343	2355656
Rash	72.49	35.23	59	2027	59499	2296500
Hypokalaemia	72.05	35.23	32	2054	10622	2345377
Alopecia	71.09	35.23	40	2046	21961	2334038
Clonus	70.07	35.23	16	2070	594	2355405
Overdose	69.25	35.23	38	2048	19869	2336130
Impaired gastric emptying	67.94	35.23	17	2069	936	2355063
Nervous system disorder	67.78	35.23	22	2064	3094	2352905
Parkinson's disease	67.06	35.23	18	2068	1308	2354691
Dizziness	66.95	35.23	56	2030	58609	2297390
Poisoning	65.79	35.23	21	2065	2799	2353200
Unresponsive to stimuli	65.47	35.23	24	2062	4852	2351147
Constipation	63.63	35.23	37	2049	21592	2334407
Respiratory syncytial virus infection	63.19	35.23	15	2071	661	2355338
Pyrexia	62.78	35.23	52	2034	53656	2302343
Muscular weakness	61.83	35.23	32	2054	14865	2341134
Cholelithiasis	61.41	35.23	24	2062	5779	2350220
Bradycardia	61.18	35.23	28	2058	9953	2346046
Drug ineffective	60.90	35.23	68	2018	101556	2254443
Loss of personal independence in daily activities	59.87	35.23	23	2063	5288	2350711
Encephalopathy	59.57	35.23	22	2064	4539	2351460
Hypomagnesaemia	59.43	35.23	19	2067	2545	2353454
Speech disorder	58.90	35.23	24	2062	6440	2349559
Chorea	58.58	35.23	12	2074	264	2355735
Phaeochromocytoma	57.81	35.23	11	2075	163	2355836
Loss of consciousness	57.57	35.23	33	2053	18734	2337265
Pruritus	57.04	35.23	45	2041	43295	2312704
Foetal death	56.21	35.23	17	2069	1895	2354104
Methaemoglobinaemia	56.12	35.23	12	2074	327	2355672
Cough	56.06	35.23	40	2046	33077	2322922
Cardiogenic shock	55.85	35.23	18	2068	2473	2353526
Suicide attempt	54.90	35.23	27	2059	11255	2344744
Respiratory failure	53.10	35.23	28	2058	13500	2342499
Hypersensitivity	53.07	35.23	34	2052	23559	2332440
Dysphagia	51.67	35.23	27	2059	12778	2343221
Pain in extremity	51.35	35.23	42	2044	42498	2313501
Skin abrasion	50.94	35.23	14	2072	1111	2354888
Bezoar	49.58	35.23	10	2076	203	2355796
Torticollis	49.56	35.23	11	2075	358	2355641
Myocardial ischaemia	49.30	35.23	16	2070	2246	2353753
Diabetes insipidus	49.30	35.23	11	2075	367	2355632
Intentional overdose	48.92	35.23	25	2061	11296	2344703
Depressed level of consciousness	48.69	35.23	22	2064	7582	2348417
Obstructive airways disorder	48.18	35.23	14	2072	1359	2354640
Hypoglycaemic seizure	47.19	35.23	9	2077	135	2355864
Dry mouth	46.97	35.23	22	2064	8231	2347768
Vascular pain	46.47	35.23	9	2077	147	2355852
Hyperreflexia	44.46	35.23	12	2074	889	2355110
Myoclonus	43.89	35.23	15	2071	2468	2353531
Abdominal pain	43.69	35.23	35	2051	34339	2321660
Muscle spasms	43.40	35.23	29	2057	21537	2334462
Pain	43.25	35.23	45	2041	61812	2294187
Porphyria acute	43.15	35.23	8	2078	102	2355897
Neuropathy peripheral	42.98	35.23	23	2063	11409	2344590
Dysarthria	42.79	35.23	19	2067	6283	2349716
Death	42.76	35.23	51	2035	81417	2274582
Respiratory dyskinesia	42.20	35.23	6	2080	10	2355989
Hepatic failure	41.37	35.23	18	2068	5671	2350328
Infusion site vesicles	41.30	35.23	7	2079	51	2355948
Deformity	41.14	35.23	10	2076	487	2355512
Acute kidney injury	40.86	35.23	31	2055	28091	2327908
Left ventricular dysfunction	40.67	35.23	12	2074	1228	2354771
Muscle rigidity	40.10	35.23	13	2073	1818	2354181
Malaise	39.85	35.23	41	2045	55544	2300455
Chest pain	38.64	35.23	30	2056	28107	2327892
Vitamin B12 decreased	38.56	35.23	9	2077	368	2355631
Off label use	38.47	35.23	46	2040	73552	2282447
Seizure like phenomena	38.46	35.23	8	2078	190	2355809
Ventricular fibrillation	37.75	35.23	13	2073	2188	2353811
Arrhythmia	37.19	35.23	17	2069	6011	2349988
Inappropriate antidiuretic hormone secretion	37.14	35.23	13	2073	2296	2353703
Mental disorder	36.90	35.23	15	2071	3992	2352007
Cogwheel rigidity	36.76	35.23	8	2078	237	2355762
Premature delivery	36.55	35.23	14	2072	3186	2352813
Oxygen saturation decreased	36.42	35.23	18	2068	7568	2348431
Coma	36.24	35.23	19	2067	9037	2346962
Vertigo	35.60	35.23	19	2067	9365	2346634
Back pain	35.53	35.23	30	2056	31629	2324370
Muscle contractions involuntary	35.47	35.23	9	2077	523	2355476
Suicidal ideation	35.31	35.23	20	2066	11067	2344932
Mental status changes	35.25	35.23	16	2070	5566	2350433

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dystonia	205.99	37.45	46	968	1968	1743799
Neuroleptic malignant syndrome	195.70	37.45	48	966	3100	1742667
Serotonin syndrome	170.61	37.45	42	972	2746	1743021
Restlessness	138.55	37.45	39	975	4282	1741485
Toxicity to various agents	133.42	37.45	62	952	29079	1716688
Drug hypersensitivity	132.12	37.45	51	963	15084	1730683
Electrocardiogram QT prolonged	120.37	37.45	37	977	5508	1740259
Premature baby	110.07	37.45	30	984	2912	1742855
Tremor	102.98	37.45	41	973	13090	1732677
Tardive dyskinesia	99.65	37.45	23	991	1129	1744638
Drug interaction	99.05	37.45	50	964	27908	1717859
Parkinsonism	95.70	37.45	23	991	1346	1744421
Extrapyramidal disorder	92.43	37.45	25	989	2352	1743415
Vomiting	92.26	37.45	53	961	38262	1707505
Nausea	90.38	37.45	58	956	51138	1694629
Dyskinesia	89.24	37.45	27	987	3792	1741975
Completed suicide	81.46	37.45	37	977	16275	1729492
Cardiac arrest	75.96	37.45	35	979	15895	1729872
Foetal exposure during pregnancy	75.72	37.45	27	987	6332	1739435
Poisoning	72.66	37.45	21	993	2511	1743256
Tachycardia	70.52	37.45	31	983	12597	1733170
Acute kidney injury	70.00	37.45	43	971	34901	1710866
Diarrhoea	66.41	37.45	49	965	53803	1691964
Loss of consciousness	62.58	37.45	30	984	14845	1730922
Muscle rigidity	56.00	37.45	16	998	1832	1743935
Pulmonary interstitial emphysema syndrome	55.57	37.45	8	1006	21	1745746
Agitation	54.89	37.45	25	989	11001	1734766
Hyperhidrosis	51.92	37.45	25	989	12463	1733304
Alveolar lung disease	51.71	37.45	8	1006	39	1745728
Drug dependence	50.68	37.45	17	997	3310	1742457
Confusional state	49.78	37.45	29	985	21249	1724518
Metabolic acidosis	49.72	37.45	19	995	5383	1740384
Anxiety	49.61	37.45	26	988	15501	1730266
Decreased appetite	49.25	37.45	30	984	23841	1721926
General physical health deterioration	47.78	37.45	24	990	13094	1732673
Torsade de pointes	47.10	37.45	13	1001	1311	1744456
Akathisia	47.06	37.45	13	1001	1315	1744452
Tonic convulsion	44.08	37.45	9	1005	245	1745522
Muscle twitching	43.14	37.45	13	1001	1789	1743978
Electrocardiogram QT shortened	42.96	37.45	7	1007	50	1745717
Gastrointestinal hypermotility	42.72	37.45	7	1007	52	1745715
Gait inability	42.70	37.45	15	999	3348	1742419
Dyspnoea	41.91	37.45	37	977	52022	1693745
Hepatocellular injury	39.45	37.45	14	1000	3217	1742550
Asthenia	39.09	37.45	30	984	34640	1711127
Diffuse alveolar damage	37.46	37.45	8	1006	272	1745495

Pharmacologic Action:

Source	Code	Description
ATC	A03FA01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS PROPULSIVES Propulsives
FDA MoA	N0000175799	Dopamine D2 Antagonists
FDA EPC	N0000175800	Dopamine-2 Receptor Antagonist
CHEBI has role	CHEBI:50919	antiemetic
CHEBI has role	CHEBI:48561	dopaminergic antagonist
CHEBI has role	CHEBI:55324	gastrointestinal drug
MeSH PA	D000932	Antiemetics
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D065127	Dopamine D2 Receptor Antagonists
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Diabetic gastroparesis	indication	34140002
Intubation of gastrointestinal tract	indication	235419001
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Chemotherapy-induced nausea and vomiting	indication	236084000
Prevention of Post-Operative Nausea and Vomiting	indication
Gastrointestinal Radiography Adjunct	indication
Suicidal thoughts	contraindication	6471006
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Cirrhosis of liver	contraindication	19943007	DOID:5082
Parkinsonism	contraindication	32798002
Depressive disorder	contraindication	35489007
Hypertensive disorder	contraindication	38341003	DOID:10763
Body fluid retention	contraindication	43498006
Mechanical ileus	contraindication	46420000
Chronic heart failure	contraindication	48447003
Gastrointestinal perforation	contraindication	51875005
Gastrointestinal hemorrhage	contraindication	74474003
Tardive dyskinesia	contraindication	102449007
Deficiency of cytochrome-b>5< reductase	contraindication	124184009
Seizure disorder	contraindication	128613002
Impaired renal function disorder	contraindication	197663003
Anastomosis of intestine	contraindication	235407009
Pheochromocytoma	contraindication	302835009
Porphyria	contraindication	418470004
Acquired torsion dystonia	contraindication	433493000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.17	acidic
pKa2	8.94	Basic
pKa3	1.08	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	7.19	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN	ANTAGONIST	Ki	6.70	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 4	GPCR	Q13639	5HT4R_HUMAN	AGONIST	EC50	6	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.40	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	5.90	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.10	DRUG MATRIX
Solute carrier family 22 member 1	Transporter	O15245	S22A1_HUMAN		IC50	4.02	CHEMBL
Aldehyde oxidase	Enzyme	Q06278	AOXA_HUMAN		IC50	4.51	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN				WOMBAT-PK
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	7.66	WOMBAT-PK
Serotonin 3 (5-HT3) receptor	Ion channel	A5X5Y0 O95264 P46098 Q70Z44 Q8WXA8	5HT3A_HUMAN 5HT3B_HUMAN 5HT3C_HUMAN 5HT3D_HUMAN 5HT3E_HUMAN		Kd	7.30	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	5.99	DRUG MATRIX
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.98	DRUG MATRIX
Serotonin 2 (5-HT2) receptor	GPCR		5HT2A_RAT 5HT2B_RAT 5HT2C_RAT		IC50	4.88	CHEMBL
Serotonin 3 receptor (5HT3)	Ion channel		5HT3A_MOUSE 5HT3B_MOUSE		Ki	6.70	CHEMBL
Adrenergic receptor alpha-2	GPCR		ADA2A_RAT ADA2B_RAT ADA2C_RAT		IC50	5.11	CHEMBL
Serotonin 1 (5-HT1) receptor	GPCR		5HT1A_RAT 5HT1B_RAT 5HT1D_RAT 5HT1F_RAT		IC50	5.11	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	6.98	CHEMBL
Serotonin 3 (5-HT3) receptor	Ion channel		5HT3A_RAT 5HT3B_RAT		Ki	6.68	CHEMBL
Adrenergic receptor alpha-1	GPCR		ADA1A_RAT ADA1B_RAT ADA1D_RAT		IC50	4.48	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_BOVIN		Ki	7.10	CHEMBL
D(3) dopamine receptor	GPCR		DRD3_RAT		IC50	7.21	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_RAT		Ki	6.05	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.26	CHEMBL
D(2) dopamine receptor	GPCR		DRD2_MOUSE	ANTAGONIST	Ki	7.54	IUPHAR
5-hydroxytryptamine receptor 4	Unclassified		5HT4R_MOUSE	AGONIST	Ki	6	IUPHAR

External reference:

ID	Source
4019835	VUID
N0000147923	NUI
C0025853	UMLSCUI
D00726	KEGG_DRUG
56549003	SNOMEDCT_US
4019835	VANDF
6915	RXNORM
372776000	SNOMEDCT_US
d00298	MMSL
004778	NDDF
CHEBI:107736	CHEBI
CHEMBL86	ChEMBL_ID
L4YEB44I46	UNII
1740	INN_ID
54143-57-6	SECONDARY_CAS_RN
DB01233	DRUGBANK_ID
4168	PUBCHEM_CID
CHEMBL1200940	ChEMBL_ID
CHEMBL1256771	ChEMBL_ID
D008787	MESH_DESCRIPTOR_UI
241	IUPHAR_LIGAND_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2203	TABLET	10 mg	ORAL	ANDA	18 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2204	TABLET	5 mg	ORAL	ANDA	18 sections
Metoclopramide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1651	TABLET	10 mg	ORAL	ANDA	14 sections
Metoclopramide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1652	TABLET	5 mg	ORAL	ANDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0576	SOLUTION	5 mg	ORAL	ANDA	19 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1576	SOLUTION	5 mg	ORAL	ANDA	19 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3414	INJECTION, SOLUTION	5 mg	INTRAMUSCULAR	ANDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1771	TABLET	10 mg	ORAL	ANDA	13 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-2536	TABLET	10 mg	ORAL	ANDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7698	TABLET	5 mg	ORAL	ANDA	18 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7752	TABLET	10 mg	ORAL	ANDA	12 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-7932	TABLET	10 mg	ORAL	ANDA	13 sections
Metoclopramide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8038	TABLET	10 mg	ORAL	ANDA	14 sections
Metoclopramide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8071	TABLET	10 mg	ORAL	ANDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8285	TABLET	10 mg	ORAL	ANDA	18 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	0703-4502	INJECTION, SOLUTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	12634-112	TABLET	10 mg	ORAL	ANDA	13 sections
METOCLOPRAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-150	TABLET	5 mg	ORAL	ANDA	14 sections
METOCLOPRAMIDE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-151	TABLET	10 mg	ORAL	ANDA	14 sections
REGLAN	HUMAN PRESCRIPTION DRUG LABEL	1	16590-906	TABLET	10 mg	ORAL	NDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0537	SOLUTION	5 mg	ORAL	ANDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0576	SOLUTION	5 mg	ORAL	ANDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	17856-3727	SOLUTION	5 mg	ORAL	ANDA	14 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	21695-346	TABLET	10 mg	ORAL	ANDA	11 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	21695-485	TABLET	5 mg	ORAL	ANDA	11 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	23155-240	INJECTION	5 mg	INTRAMUSCULAR	ANDA	13 sections
Metoclopramide	HUMAN PRESCRIPTION DRUG LABEL	1	33261-166	TABLET	10 mg	ORAL	ANDA	13 sections
METOCLOPRAMIDE hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	40032-581	TABLET, ORALLY DISINTEGRATING	5 mg	ORAL	ANDA	17 sections
Metoclopramide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42254-196	TABLET	5 mg	ORAL	ANDA	14 sections
Metoclopramide Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	42254-266	TABLET	10 mg	ORAL	ANDA	14 sections